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ABSTRACT
Introduction: Lupus nephritis is a serious complication of systemic lupus erythematosus. Currently, therapy is guided by findings in the 
renal biopsy, following the International Society of Nephrology / Renal Pathology Society classification. Austin and Hill’s histomorpho-
logical indexes are not routinely obtained. In this retrospective single-centre study, we aimed to analyze the importance and applicability 
of the different morphological indexes in predicting response to treatment and prognosis.
Material and Methods: Patients with kidney biopsy demonstrating lupus nephritis from the 2010 – 2016 period were included. We ana-
lyzed their demographic data, comorbidities, clinical presentation and laboratorial evaluation at the time of renal biopsy. We evaluated 
the following outcomes: clinical remission, renal function and proteinuria at end of follow-up. Histologic analysis was performed using 
the International Society of Nephrology / Renal Pathology Society classification and the morphological indexes described by Austin 
(Activity and Chronicity) and Hill. Univariate and multivariate statistical analysis was performed using STATA software.
Results: We analyzed 46 biopsy-proven lupus nephritis cases, with a median follow-up of 31.9 (13.2 – 45.6) months. Based on 
biopsy findings, 35 patients were started on immunosuppressive therapy. We observed that Class IV patients had, at presentation, 
lower estimated glomerular filtration rate (67.3 vs 94.6 mL/min; p = 0.02), higher proteinuria (4.26 vs 2.37 g/24 hours; p = 0.02) and a 
non-significantly higher C3 consumption (58.9 vs 77.4 mg/dL; p = 0.06). We did not observe correlations between International Society 
of Nephrology / Renal Pathology Society classification and the outcomes at the end of follow-up. In contrast, both the Hill biopsy index 
and Austin’s Chronicity index were correlated with renal function and proteinuria at the end of follow-up. Austin’s Activity index correlat-
ed with the immunological findings (C3, C4 and anti-dsDNA) at presentation.
Discussion: Because clinical activity poorly correlates with histologic activity, histological findings are fundamental when assessing 
patients with suspected lupus nephritis. The most recent International Society of Nephrology / Renal Pathology Society report supports 
the European League Against Rheumatism guidelines, encouraging the adoption of histomorphological indexes when evaluating lupus 
nephritis. Our data, showing a correlation between the renal outcomes and the indexes described by Austin and Hill, supports this view.
Conclusion: The histomorphological indexes in lupus nephritis are easily obtainable, can predict renal outcomes and may help in the 
management of such patients.
Keywords: Biopsy; Kidney/pathology; Lupus Erythematosus, Systemic/complications; Lupus Nephritis Predictive Value of Tests; 
Prognosis
RESUMO
Introdução: A nefrite lúpica é uma complicação grave do lúpus eritematoso sistémica. Atualmente, a terapêutica dirigida é ditada 
pelos achados histológicos da biópsia renal, através da classificação da International Society of Nephrology / Renal Pathology Society. 
Os índices histomorfológicos descritos por Austin e Hill não são rotineiramente realizados. Neste estudo retrospetivo unicêntrico, pro-
curámos analisar a aplicabilidade e relevância dos índices morfológicos na predição da resposta à terapêutica e do prognóstico em 
doentes com nefrite lúpica.
Material e Métodos: Foram incluídos doentes cuja biópsia renal, realizada entre 2010 e 2016, documentava nefrite lúpica. Analisá-
mos os dados demográficos, comorbilidades, apresentação clínica e avaliação laboratorial destes doentes correspondente à altura 
da biópsia renal. Avaliámos os seguintes outcomes: remissão clínica, função renal e proteinúria no final do seguimento. A avaliação 
histológica foi realizada segundo a classificação da International Society of Nephrology / Renal Pathology Society e aplicando os 
índices morfológicos descritos por Austin (Actividade e Cronicidade) e Hill. A análise estatística univariada e multivariada foi realizada 
com software STATA.
Resultados: Foram revistos 46 casos de nefrite lúpica, com um follow-up mediano de 31,9 (13,2 – 45,6) meses. A partir dos achados 
histológicos, 35 doentes foram submetidos a imunossupressão. Observámos que os doentes com nefrite lúpica Classe IV tinham, à 
apresentação, taxa de filtrado glomerular estimada mais reduzida (67,3 vs 94,6 mL/min; p = 0,02), proteinúria mais elevada (4,26 vs 
2,37 g/24 horas; p = 0,02) e consumo de C3 mais elevado de modo não-significativo (58,9 vs 77,4 mg/dL; p = 0,06). Não se verificou 
correlação entre a classificação ISN/RPS e os desfechos no final do follow-up. Por outro lado, tanto o índice de Hill quanto o score 
de cronicidade de Austin correlacionaram-se com a função renal e a proteinúria no final do seguimento. Adicionalmente, o score de 
atividade de Austin correlacionou-se com os achados imunológicos à apresentação (C3, C4 e anti-dsDNA).
Discussão: Uma vez que a actividade clínica tem fraca correlação com a actividade histológica, os achados histológicos são fun-
damentais durante a avaliação na suspeita de nefrite lúpica. A mais recente revisão da International Society of Nephrology / Renal 
Pathology Society vai ao encontro das linhas de orientação da European League Against Rheumatism, encorajando a aplicação de 
índices histomorfológicos na avaliação da nefrite lúpica. Os dados da nossa população, onde verificámos uma correlação entre o 
prognóstico renal e os índices histomorfológicos descritos por Austin e Hill, apoiam essa sugestão.
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Table 1 – Abbreviated lupus nephritis ISN/RPS classification
Class Definition
Class I Minimal mesangial lupus nephritis
Class II Mesangial proliferative lupus nephritis
Class III Focal lupus nephritis
Class IV Diffuse lupus nephritis
Class V Lupus membranous nephropathy
Class VI Advanced sclerosing lupus nephritis
Conclusão: Os índices histomorfológicos na nefrite lúpica são de fácil aplicação, conseguem prever os outcomes clínicos e podem 
representar uma ferramenta adicional na avaliação dos doentes com nefrite lúpica.
Palavras-chave: Biópsia; Lupus Eritematoso Sistémico/complicações; Nefrite Lúpica; Prognóstico; Rim/patologia; Valor Preditivo dos 
Testes
INTRODUCTION
Systemic lupus erythematosus (SLE) is a systemic 
autoimmune disease associated with significant comorbid-
ity and mortality.1 Lupus nephritis (LN) is one of its most 
serious complications and includes a wide spectrum of 
clinical presentations, ranging from isolated haematuria to 
end-stage renal disease. Immunosuppression can have an 
important role in controlling renal affection — with current 
therapies, a high remission rate is observed, which is the 
most important renal prognostic factor.2 For those reasons, 
lupus nephritis requires a well-weighted diagnostic and 
therapeutic approach for which renal biopsy currently occu-
pies a central role.
The International Society of Nephrology/Renal 
Pathology Society (ISN/RPS) lupus nephritis classification 
is widely used and recommended in current guidelines.3 
Histology findings allow the sub-classification into six class-
es (I – VI), as shown in Table 1. The most recent report4 and 
EULAR guidelines5 additionally recommend the use of mor-
phological indexes; these have been originally described by 
Austin et al,6 who defined two indexes (activity and chronic-
ity), using a semi-quantification of findings. This was fur-
ther studied by Hill et al,7 who modified previous indexes, 
improving its prognostic value. Subcategorization of class 
III and IV into active, chronic or both is also suggested to be 
replaced by this semi-quantification method.4
Histomorphology has been of paramount importance 
in defining the field of nephrology. The quantification of 
microscopy findings has found its place in renal transplan-
tation through the semi-quantitative Banff criteria.8 In LN, 
while the ISN/RPS classification is routinely used, Austin 
and Hill indexes are not. The aim of this study was to ana-
lyze the applicability and the efficacy of the different LN 
morphological indexes in predicting response to treatment 
and prognosis.
MATERIAL AND METHODS
This is a retrospective single-centre descriptive analysis 
of consecutive SLE and biopsy-proven LN patients, diag-
nosed from 2010 to 2016. Patients whose kidney biopsies 
were found to be inadequate due to an insufficient num-
ber of glomeruli (defined as less than five) were excluded. 
Patients’ data were obtained from clinical files. We analyzed 
patients’ demographic data (age, gender, race), comorbid-
ities and their duration (including SLE history and previous 
manifestations and medications), hypertension according 
to the most recent definition by the European Society of 
Cardiology,9 clinical presentation and laboratorial evaluation 
at the time of renal biopsy [including full blood count, serum 
creatinine, urinalysis, proteinuria (24 hours-collection or uri-
nary protein to creatinine ratio in a random urine sample), 
C3, C4 and anti-dsDNA].
The following outcomes were evaluated: clinical remis-
sion, renal function and proteinuria (g/24 hours) at end of 
follow-up (FUP). The LUNAR trial10 definition for clinical 
remission was used: complete remission was defined as 
reduction of proteinuria to < 0.5 g/24 hours, inactive urinary 
sediment and normal serum creatinine level if it was abnor-
mal at baseline (or a serum creatinine level of < 115% of 
baseline if it was normal at baseline); partial remission was 
defined as a reduction in proteinuria to < 1 g/24 hours if 
initial level < 3 g/24 hours (or reduction to < 3 g/24 hours if 
initial level > 3 g/24 hours), inactive urinary sediment and 
a serum creatinine level of < 115% of baseline. All renal 
biopsies were performed after obtaining the patient's written 
consent. The histologic optic examination was performed 
with hematoxylin and eosin, periodic acid–Schiff, Jones’ 
silver and Masson’s trichrome stains; immunofluorescence 
study included studies with antibodies against IgG, IgA, 
IgM, C3, C4, C1q and fibrinogen.
The studied predictors were the ISN/RPS LN classifi-
cation and the morphological indexes described by Austin 
(activity and chronicity)6 and Hill,7 obtained after histomor-
phological review of renal biopsies. Both scores describe 
findings in a quantitative fashion (zero to 3+). Austin’s activ-
ity score measures active LN findings of glomerular prolifer-
ation, leucocyte exudation/karyorrhexis, fibrinoid necrosis, 
cellular crescents, hyaline deposits and interstitial inflam-
mation; Austin’s chronicity score contains chronic irrevers-
ible LN findings: glomerular sclerosis, fibrous crescents, 
tubular atrophy and interstitial fibrosis.
Hill’s biopsy index slightly adapted Austin’s activity and 
chronicity scores and added histological signs of tubuloin-
terstitial activity (including tubular cell necrosis and flatten-
ing and the presence of macrophages or epithelial cells in 
tubular lumens) and immunofluorescence findings (includ-
ing glomerular, tubulointerstitial and vascular deposition). 
Regarding the latter, in the review of our samples, we did 
not re-perform immunofluorescence and instead used the 
findings described in our original report. Table 2 summariz-
es both indexes.
Renal function was monitored by serum creatinine 
and estimated glomerular filtration rate (eGFR) using 
the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation.
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Data are presented as frequencies for categorical varia-
bles; continuous variables are presented as median (inter-
quartile range).
One-way ANOVA was used for comparisons between 
the different indications for kidney biopsy, the laboratory 
data and the morphologic data obtained after the applica-
tion of the different morphological indexes; chi-square test 
of independence/Fisher’s exact test was performed when 
comparing the different indications for kidney biopsy and the 
ISN/RPS LN classes. Associations between the different LN 
classes and clinical and laboratory variables were investi-
gated using Fisher’s exact test and Wilcoxon. Associations 
between Austin and Hill indexes and laboratory variables 
were investigated using Spearman test.
After this first analysis, we fitted a model of multivariate 
analysis using all subjects and defining the chronicity index-
es as our main predictors and eGFR at the end of follow-up 
as our main outcome. Age, gender and proteinuria were the 
variables used as potential confounders (older patients may 
have a lower renal function, women tend to have lower GFR 
and proteinuria is associated with a rapid decline of renal 
function). All tests were performed using STATA software 
version 13, and a p-value < 0.05 was considered statistical-
ly significant.
Given the nature of this analysis (retrospective and 
observational) and the anonymization of the collected data, 
authorization from the ethics committee and the Portuguese 
Data Protection Authority was not required.
RESULTS
From 2010 to 2016, we found 46 biopsy-proven LN 
cases in our unit. The patients’ median age was 35 years 
(27 – 42), and 84.8% (n = 39) were women, in a mostly 
Caucasian population (56.5%; n = 26). In seven patients, 
SLE diagnosis was previously unknown, while the remain-
ing 39 patients had SLE for a median of 3.96 (1.1 – 11.9) 
years, resulting in treatment with hydroxychloroquine in 
46.1% and additional immunomodulation in 76.9% of cas-
es. At presentation, median creatinine was 0.8 (0.6 – 1.4) 
mg/dL, corresponding to a median eGFR of 89 (46.9 – 117) 
mL/min; median level of proteinuria was 2.45 (1 – 4.4) g/day; 
34.7% (n = 16) of patients were hypertensive and 58.7% 
(n = 27) had haematuria at presentation. We classified our 
patients according to the indication for renal biopsy: 18 had 
asymptomatic urinary abnormalities, 16 nephrotic-range 
proteinuria (proteinuria > 3.5 g/d) and 12 renal insufficiency 
(eGFR < 45 ml/min). The histomorphological findings are 
summarized in Table 3.
Regarding histology, sample quality was adequate, the 
minimum number of glomeruli per sample was five and we 
had a maximum of 30 glomeruli, with a median of 11 glo-
meruli (7.75 – 14.25). The 46 patients were evaluated dur-
ing a median follow-up of 31.9 months (13.2 – 45.6) months. 
Table 2 – Morphological indexes scoring system. (A) Austin’s activity and chronicity indexes; (B) Hill biopsy index
B:
Components Score
Glomerular Activity index 0 – 3
Tubulointerstitial Activity index 0 – 4
Chronic lesions index 0 – 2
Immunofluorescence index 0 - 3
Total 0 – 12
A:
Activity index Score
Endocapillary hypercellularity 0 – 3
Neutrophils/karyorrhexis 0 – 3
Fibrinoid necrosis (0 - 3) x 2
Hyaline deposits 0 – 3
Cellular/fibrocellular crescents (0 – 3) x 2
Interstitial Inflammation 0 – 3
Total 0 – 24
Chronicity index Score
Total glomerulosclerosis score 0 – 3
Fibrous crescents 0 – 3
Tubular atrophy 0 – 3
Interstitial fibrosis 0 – 3
Total 0 – 12
Table 3 – Renal clinical characteristics and histomorphology findings
Clinical presentation Patients Class II Class III Class IV Class V Austin’s Activity Index
Austin’s 
Chronicity 
Index
Hill Biopsy 
Index
Asymptomatic urinary 
abnormalities 18 44% 17% 28% 11%
3.03
(0 – 6)
1.50
(0 – 2.63)
0.86
(0.14 – 1.53)
Nephrotic syndrome 
(proteinuria > 3.5 g/d) 16 0% 25% 63% 31%
6.59
(1.65 – 10)
2.66
(1 – 3)
1.63
(0.76 – 2.27)
Renal insufficiency 
(eGFR < 45 ml/min) 12 0% 8% 75% 17%
6.95
(0.5 – 13)
3.73
(0.5 – 7)
1.96
(1.56 – 2.56)
p-value — < 0.001 NS 0.02 NS 0.07 0.08 0.007
eGFR: estimated glomerular filtration rate; NS: non-significant. LN Classes (from II to V) frequencies are expressed for each renal clinical 
characteristic (asymptomatic urinary abnormalities | nephrotic syndrome | renal disease). Median indexes (Austin activity and chronicity 
and Hill biopsy) are expressed for each renal clinical characteristic (asymptomatic urinary abnormalities | nephrotic syndrome | renal dis-
ease). The analysis of the proportions between renal characteristics and LN classes was performed using Fisher exact test; the analysis 
of the variance of the different indexes was performed using one-way ANOVA.
A
R
TIG
O
 O
R
IG
IN
A
L
Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com638
Navarro D, et al. Morphological indexes: can they predict lupus nephritis outcomes? Acta Med Port 2019 Oct;32(10):635–640
Based on biopsy findings, immunosuppressive therapy 
was started/intensified on 36 patients — induction therapy 
with cyclophosphamide in 50% and mofetil mycophenolate 
(MMF) in the remaining 50%; MMF was used as mainte-
nance therapy in 80.6% (n = 29) of patients, azathioprine 
being the choice for the other seven patients. Excluding 
patients with ongoing induction immunosuppression, clini-
cal remission was obtained in 93.8% (30/32) of patients — 
we observed 15 complete, 15 partial remissions and four 
patients suffered LN recurrence.
By the end of follow-up, two patients (4.3%) died due to 
septic shock, one of them having developed end-stage renal 
disease secondary to LN. The remaining 95.7% (n = 44) 
had a median serum creatinine of 0.8 mg/dL (0.7 – 0.99), 
eGFR of 99.8 mL/min (71.2 – 116.8) and proteinuria of 
0.6 g/24 hours (0.2 – 1.6).
Using Wilcoxon test, we observed that patients classi-
fied as ISN/RPS class IV had, at presentation, lower eGFR 
(67.3 vs 94.6 mL/min; p = 0.01), higher proteinuria (4.26 vs 
2.37 g/24 hours; p = 0.002) and non-significant reduction in 
C3 serum levels (58.9 vs 77.4 mg/dL; p = 0.06). We found 
no correlation between the different ISN/RPS LN classes 
and clinical outcomes, including end of follow-up renal func-
tion or proteinuria. We did, however, find several correla-
tions between clinical findings (both at presentation and at 
the end of follow-up) and the activity and chronicity histo-
morphological indexes, as described in Table 4.
Using the Spearman test, we observed that the Activity 
index correlated with the immunological findings at pres-
entation — C3, C4 and anti-dsDNA. More importantly, both 
the Hill biopsy index and the Chronicity index were correlat-
ed with renal function and proteinuria at the end of follow-up, 
and hence a predictor of unsuccessful clinical remission. No 
individual histological finding of the indexes could, by itself, 
predict clinical remission.
In the multivariate model, the chronicity index was 
inversely correlated with eGFR, using age, gender, and 
initial proteinuria as potential confounders (p-value of the 
model 0.02).
DISCUSSION
Management of SLE patients can be complex, being 
especially challenging to attain disease control without 
causing iatrogenesis. For this reason, many efforts are put 
into the elaboration and refining of disease activity index-
es.11 The same holds true for LN, especially since some of 
the clinical parameters we rely on for renal disease (serum 
creatinine and proteinuria) can represent both active dis-
ease — that may be treated with further immunosuppres-
sion — and chronic damage — which would not benefit 
from additional immunomodulation. For those reasons, clin-
ical remission definitions in LN are many and rarely agreed 
upon.12 More importantly, clinical activity poorly correlates 
with histologic activity,13 further complicating clinical deci-
sions. To mitigate this, some centers are routinely perform-
ing repeat renal biopsies regardless of clinical indication.14
Nephrologists rely heavily on histomorphological find-
ings in LN, and general agreement is that immunosuppres-
sion should be started when the ISN/RPS classification 
suggests the patient has an active proliferative disease 
(class III or IV with activity signs) or a severe membranous 
LN (class V); treating renal affection with immunosuppres-
sive drugs for other classes is typically not recommended. 
Some limitations to the ISN/RPS classification need to be 
considered, starting with the fact that it is, by definition, glo-
merulocentric, leaving little to no space to the description 
of the full spectrum of histomorphological manifestations of 
LN. This confers an almost dichotomic-aura (i.e. treat / don’t 
treat) to the current classification and hampers the intro-
duction of diagnostic subtleties such as lupus podocytopa-
thy.15 Another issue is that while nephrologists are sensible 
to findings such as tubular atrophy and interstitial fibrosis, 
until the last update, ISN/RPS failed to account for tubuloin-
terstitial lesions adequately. Injury to the tubulointerstitial 
compartment appears to poorly correlate with glomerular 
lesions,16,17 suggesting independent immunological path-
ways, which were oversimplified by the ISN/RPS classifica-
tion — this raises the question if the tubulointerstitial activ-
ity should itself be an indication for immunosuppressive 
Table 4 – Correlations between clinical parameters and histomorphological indexes
Austin’s Activity Index Austin’s Chronicity Index Hill Biopsy Index
R p R p R p
Presentation
Anti-dsDNA (IU/mL) 0.3 0.05 –0.07 NS 0.2 NS
C3 (mg/dL) –0.3 0.03 0.1 NS -0.2 NS
C4 (mg/dL) –0.3 0.04 0.1 NS –0.2 NS
Serum creatinine (mg/dL) 0.1 NS 0.3 0.03 0.3 0.03
eGFR (ml/min) –0.3 NS –0.4 0.004 –0.5 0.001
Proteinuria (g/24h) 0.4 0.009 –0.3 0.006 0.6 0.0001
End of follow-up
Serum creatinine (mg/dL) 0.07 NS 0.4 0.002 0.3 0.046
eGFR (mL/min) 0.09 NS –0.5 0.002 –0.2 NS
Proteinuria (g/24h) 0.2 NS 0.3 0.03 0.4 0.02
eGFR: estimated glomerular filtration rate. All correlations were made using Spearman correlation in a univariate analysis.
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therapy. Furthermore, and perhaps most importantly, there 
is an increasing body of evidence showing that tubuloin-
terstitial lesions are the most significant prognostic indi-
cator in LN.17,18 It is therefore not surprising that, despite 
being extensively used, the ISN/RPS classification could 
not predict clinical outcomes. This has led to the develop-
ment of the indexes described by Austin and later by Hill, 
which have proven capable of estimating renal outcomes 
from the renal biopsy findings. Their integration in the most 
recent ISN/RPS classification reflects its importance. In an 
era of a continuous search for more sophisticated therapeu-
tic strategies,19,20 it’s surprising that so little emphasis had 
been given to improve upon our current clearly insufficient 
diagnostic methods. Despite being ‘old news’, morpholog-
ical indexes have the potential to introduce a more refined 
approach to diagnosis and treatment, similar to what the 
Banff criteria offer to the renal transplantation field.
Our first goal was to evaluate the applicability of such 
scores: despite not being familiar with them and requiring 
an additional effort, we had no substantial difficulty in their 
application. The second goal was to evaluate their useful-
ness in predicting response to treatment and prognosis. 
As shown in Table 3, we observed an association between 
clinical presentation and the ISN/RPS classification. The 
same is valid for Hill’s biopsy index and Austin’s Activity 
and Chronicity indexes. However, when considering out-
comes at the end of follow-up, the ISN/RPS classification 
added little, while the morphological indexes can predict 
outcomes (Table 4).
Based on these findings, although we feel morphologi-
cal indexes are useful in LN, some limitations are observ-
able: i) we only reviewed light microscopy findings and did 
not re-perform immunofluorescence; ii) it is a retrospective 
single-centre study, with a fairly low number of patients lim-
iting our conclusions — for instance, we would have liked 
to further examine the role of the indexes with different 
immunosuppressive drugs, which were not apparent in 
our population. Further analysis with a larger number of 
patients could shed some light on this subject, potential-
ly identifying the patients who require a more aggressive 
therapeutic approach.
CONCLUSION
In summary, the most recent ISN/RPS consensus rec-
ognizes the efficacy of histomorphological indexes in the 
evaluation of LN, and our data supports that. We observed 
a significant correlation between the renal outcomes and 
the indexes described by Austin and Hill. We encourage 
other units to include morphological indexes in their evalu-
ation of such patients, as they are easily applicable scores 
and may provide a useful and individualized quantitative 
measure of clinical outcomes.
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